** Shares of cancer diagnostic test maker Grail GRAL.O fall 18.8% to $34.81 in extended trading
** Company's Q1 revenue of $31.8 million misses analysts' average expectation of $35.2 million, according to data compiled by LSEG
** GRAL reports quarterly loss of $3.10/shr, vs analysts' average estimate of $4.09/shr
** Up to last close, stock up more than double YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.